Feed/Companies/Aspen Neuroscience

Aspen Neuroscience

As of 14 Oct 2026, Aspen Neuroscience has raised $115M across 1 verified round on record; latest: $115 million Series C led by Arch Venture Partners, Frazier Life Sciences and 2 others, announced 20 Nov 2025.

BUILT ON

Visit site

Aspen Neuroscience develops personalized regenerative therapies, specifically autologous iPSC-derived cell replacement therapies for Parkinson's disease.

aspenneuroscience.comLinkedInSan Diego

LATEST ROUND

Series C

$115M · 2025-11-20

RAISED ON RECORD · USD

$115M

across 1 verified round

INVESTORS

4 leads

SOURCES

from 1 publisher

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Series C

$115M · 2025-11-20

[ HISTORY ]

led by Arch Venture Partners, Frazier Life Sciences, OrbiMed, Revelation Partners

Round	Amount	Announced	Lead	Buzz
Series C [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$115M $115M incl. grants	2025-11-20	Arch Venture Partners, Frazier Life Sciences, OrbiMed, Revelation Partners	No recent discussion
1 source [ VERIFIED · CORRECTED ] read against 1 source Amount added $115 million · prnewswire.com HQ added San Diego · prnewswire.com The source names additional investors as “among others” and “others,” but does not identify them. Published by hand (prnewswire.com): "20, 2025 /PRNewswire/ -- Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million Series C financing round.": Checked by hand: Aspen's own release states the $115M Series C.

Aspen Neuroscience

Company

Rounds

Sources

Profile

Investors

Aspen Neuroscience

Rounds

Profile

Sources

Series C$115M2025-11-201 source

Investors

Series C$115M2025-11-2013 investors